0148.KLSE Sunzen Biotech Bhd
- Market cap
- MYR 174M
- P/E
- 22.0x
- P/B
- 1.54x
- ROE
- 3.6%
- Dividend yield
- 0.89%
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2024.
Is 0148.KLSE undervalued?
Graham number0148.KLSE trades 22.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sunzen Biotech Bhd fundamental analysis
8 of 22 checks passedROE 0/2
Low return on equity (3.6%), below 10%.
ROA 0/1
Return on assets (3.0%) is below the industry median (4.4%).
Profit Consistency 1/2
Profitable for 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (30.3%) is above the industry median (-1.6%).
Revenue Growth 1/2
Revenue grew 1.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (4.8%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is negative, against interest expense, below 5x.
PE vs Market 0/1
PE (22.0x) is above the market median (11.4x).
PE vs Industry 0/1
PE (22.0x) is above the industry median (10.2x).
PBV 0/1
Price to book (1.5x) is above the industry median (0.8x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 33.9, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
About Sunzen Biotech Bhd
Sunzen Group Berhad, an investment holding company, engages in the biotechnology research and development, manufacturing, and marketing of animal feed supplement products in Malaysia, China, Singapore, and internationally. It operates through Human Health, Medical Devices and Services, and Loan Financing segments. The company provides veterinary, pharmaceutical, chemical products, animal health, and beauty and cosmetic products. It also offers financial consultancy services …
Full company profileSunzen Biotech Bhd financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sunzen Biotech Bhd annual financial statements (MYR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 40.0M | 303M | 296M | 241M | 82.2M | 90.5M | 97.1M | 85.8M | 89.1M |
| Gross Profit | 7.64M | 11.5M | 11.2M | 11.7M | 7.99M | 15.9M | 23.9M | - | - |
| Operating Income | -256K | 4.11M | -6.89M | -19.1M | -12.1M | 3.92M | 7.63M | 4.69M | 26.4M |
| EBITDA | - | 5.10M | -4.26M | -15.8M | -9.44M | 6.57M | 10.2M | - | - |
| Net Income | -130K | 3.47M | -6.94M | -16.3M | -13.2M | 680K | 3.75M | 4.94M | 4.75M |
| EPS | 0.00 | 0.01 | -0.01 | -0.03 | -0.03 | 0.00 | 0.01 | 0.01 | 0.01 |
| Balance Sheet | |||||||||
| Total Assets | 106M | 119M | 148M | 128M | 123M | 149M | 151M | 170M | 159M |
| Total Liabilities | 8.98M | 19.7M | 40.6M | 37.0M | 35.7M | 30.6M | 29.1M | 20.5M | 18.7M |
| Shareholders' Equity | 97.2M | 99.5M | 107M | 91.4M | 87.5M | 118M | 122M | 140M | 131M |
| Cash & Short-term Investments | 50.6M | 47.4M | 41.5M | 32.8M | 38.9M | 47.2M | 12.2M | 21.5M | 19.4M |
| Total Debt | - | - | 5.89M | 15.6M | 5.24M | - | - | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | 256K | 4.02M | -4.07M | -11.0M | 7.20M | -16.4M | -32.1M | 819K | - |
| Capital Expenditure | 6.64M | 3.42M | 1.94M | 4.02M | 1.16M | 2.40M | 2.47M | 1.01M | 0.00 |
| Free Cash Flow | - | 603K | -6.00M | -15.1M | 5.44M | -18.8M | -34.3M | -192K | - |
| Ratios | |||||||||
| ROE | -0.1% | 3.5% | -6.5% | -17.8% | -15.1% | 0.6% | 3.1% | 3.5% | 3.6% |
| ROA | -0.1% | 2.9% | -4.7% | -12.7% | -10.7% | 0.5% | 2.5% | 2.9% | 3.0% |
| Net Profit Margin | -0.3% | 1.1% | -2.3% | -6.8% | -16.1% | 0.8% | 3.9% | 5.8% | 5.3% |
| Debt to Equity | - | - | 0.06x | 0.17x | 0.06x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sunzen Biotech Bhd dividends
- Dividend yield
- 0.89%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 12, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | MYR 1.44M | 0.00 | 41.6% |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Apr 29, 2015.
Who owns Sunzen Biotech Bhd
- Insiders 82.17%
- Institutions 0.00%
- Public & others 17.83%
- Shares outstanding 790M
- Free float 167M
Sunzen Biotech Bhd company profile
- Company name
- Sunzen Biotech Bhd
- Ticker
- 0148.KLSE
- ISIN
- MYQ0148OO005
- Exchange
- Kuala Lumpur Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 168
- Fiscal year end
- December
- Address
- No. 13, Jalan Anggerik Mokara 31/47, Shah Alam, Malaysia, 40460
- Phone
- 60 3 5122 9333
- Website
- sunzengroup.com
About Sunzen Biotech Bhd
Sunzen Group Berhad, an investment holding company, engages in the biotechnology research and development, manufacturing, and marketing of animal feed supplement products in Malaysia, China, Singapore, and internationally. It operates through Human Health, Medical Devices and Services, and Loan Financing segments. The company provides veterinary, pharmaceutical, chemical products, animal health, and beauty and cosmetic products. It also offers financial consultancy services and licensed money lending activities; manufactures and sells traditional Chinese medicine; trades in crude palm oil and derivative products; and manufactures, imports, trades in, exports, and sells bird's nests and related products. In addition, the company retails herbal drinks, foodstuffs, hampers, and related health products. Further, it engages in the wholesale and trading of animal health and nutrition products for livestock, animal beauty, and cosmetic products; and retail, wholesale, distribution, and trading of health and herbal products, as well as manufacturing, trading, marketing, e-commerce, sales of food and beverage nutrition products. Additionally, the company trades in ophthalmic and diagnostic equipment and other related products. The company was formerly known as Sunzen Biotech Berhad and changed its name to Sunzen Group Berhad in December 2024. Sunzen Group Berhad was founded in 1998 and is based in Shah Alam, Malaysia.
Sunzen Biotech Bhd management
6- Mr. Chee Pun ChingExecutive Chairman · born 1972
- Mr. Yek Ming TeoGroup MD & Executive Director · born 1984
- Mr. Tong Eng PhangChief Financial Officer · born 1964
- Mr. Wee Chun LimSales & Marketing Director · born 1981
- Ms. Xin Yee GohCompany Secretary
- Tsae Yng QwikCompany Secretary